Invited presentation followed by panel discussion on the next wave of innovation in immunotherapy of cancer: Paul Peter Tak, M.D., Ph.D., ...

Minimal residual disease (MRD)-guided retreatment with anti-CD20 antibodies effectively lowers MRD levels and delays clinical relapse in patients with high-risk chronic lymphocytic leukemia (CLL), ...

BD rides high on product demand across segments, but fourth-quarter fiscal 2025 results may face pressure from global market ...

Waters Corp reports record Q3 2025 sales and profit growth, raises full-year guidance, and highlights new product launches and BD deal synergies.

Urolithin A, a natural postbiotic known to trigger mitophagy, rejuvenated key immune cell functions in healthy middle-aged ...

A lower number of CD26+ LSCs at diagnosis correlates with optimal molecular response in CML patients at 3, 12, and 24 months.

Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present 21 abstracts, including 5 oral presentations, ...